Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population

Chinese Medical Journal

Volumn 119, Issue 14, 2006, Pages 1204-1209

  He, Xiao Ming ^a,f   Zhang, Zhen Xin ^a   Zhang, Jun Wu ^b   Zhou, Yong Tao ^a   Tang, Mou Ni ^c   Wu, Cheng Bin ^d   Hong, Zhen ^e  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c SICHUAN UNIVERSITY   (China)

^d XI'AN JIAOTONG UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer disease; Gene; Paraoxonase 1; Single nucleotide polymorphism

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE 1; GLUTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENOTYPE; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTPATIENT DEPARTMENT; POLYMERASE CHAIN REACTION; POPULATION RESEARCH;

EID: 33746362925     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607020-00013     Document Type: Article

References (23)

1. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664-670.
2. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, et al. Apolipoprotein E isoforms and apolipoprotein Al protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem 2004; 91:1312-1321.
3. Roses AD. Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 1998; 81:49-57.
4. Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr Opin Lipidol 2002; 13:289-294.
5. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 1998; 252:711-715.
6. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
7. Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998; 806:271-273.
8. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002; 252:63-67.
9. Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 1993; 87:35-48.
10. Germer S, Holland MJ, Higuchi R. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Research 2000; 10:258-266.
11. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73-76.
12. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498-507.
13. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334-336.
14. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9: 745-753.
15. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69:541-550.
16. Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, et al. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999; 9:755-761.
17. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510-2517.
18. Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001; 34:475-481.
19. Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, et al. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology 1999; 53:1146-1148.
20. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci 2002; 977:239-244.
21. Pola R, Gaetani E, Flex A, Gerardino L, Aloi F, Flore R, et al. Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON1 gene in an Italian population. Dement Geriatr Cogn Disord 2003; 15:88-91.
22. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM. Different pattern of association of paraoxonase Gln192->Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett 2003; 339:17-20.
23. Pola R, Flex A, Ciaburri M, Rovella E, Rovella E, Valiani A, et al. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: A possible role for the 192 Q/R polymorphism of the PON1 gene. Neurosci Lett 2005; 382:338-341.